Intelligent Bio Solutions (INBS) Common Equity (2019 - 2025)

Intelligent Bio Solutions has reported Common Equity for 7 years, with the latest figure at $2.8 million in Q2 2025.

• For the quarter ending Q2 2025, Common Equity fell 65.61% year-over-year to $2.8 million; the trailing twelve-month figure through Jun 2025 stood at $2.8 million (down 65.61% YoY), and the FY2025 full-year result was $2.8 million, down 65.61% from the prior year.
• Common Equity for Q2 2025 stood at $2.8 million, down from $4.9 million in the prior quarter.
• The five-year high for Common Equity was $15.9 million in Q1 2021, with the low at $1.2 million in Q3 2023.
• Average Common Equity over 5 years is $7.6 million, with a median of $6.2 million recorded in 2022.
• Year-over-year, Common Equity surged 543.02% in 2021 and plunged 76.2% in 2023.
• Tracing INBS's Common Equity over 5 years: stood at $10.0 million in 2021, then climbed by 2.17% to $10.3 million in 2022, then tumbled by 69.27% to $3.2 million in 2023, then soared by 33.26% to $4.2 million in 2024, then slumped by 33.06% to $2.8 million in 2025.
• The last three Common Equity figures came in at $2.8 million (Q2 2025), $4.9 million (Q1 2025), and $4.2 million (Q4 2024), per Business Quant data.

Peer Comparison